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There is increasing evidence that abnormalities of
cellular DNA within primary tumours are of prog-
nostic significance. Deviation from the normal
diploid DNA content of tumour cells has been
associated with a poorer prognosis in carcinomas of
the breast (Friedlander et al., 1984a), ovary
(Friedlander et al., 1984b) and colon (Wolley et al.,
1982). However, in the more advanced stages of
malignant disease the association between DNA
aneuploidy and prognosis does not appear to be so
prominent (Hedley et al., 1985). With the current
resurgence of interest in various forms of therapy
for liver metastases from primary colorectal cancer
e.g. hepatic resection, regional or systemic chemo-
therapy, hepatic arterial ligation and hepatic
irradiation, it is of importance to assess the various
prognostic factors that may influence the natural
history. Several workers have identified a variety of
indices which may be of use in assessing survival or
for stratification within controlled clinical trials
(Goslin et al., 1982; Lahr et al., 1983; Finan et al.,
1985). In order to assess the value of ploidy in
patients with advanced colorectal disease, we have
studied a series of patients presenting with
synchronous hepatic metastases from primary
colorectal cancer whose survival has been
documented and in whom the primary tumour was
suitable for measurement of DNA content. Ploidy
has then been compared with other well recognised
prognostic variables.
From a retrospective study of 94 patients with
colorectal cancer and synchronous hepatic metas-
tases presenting to the two major teaching centres
in Leeds over the period 1976-80,46 cases, in whom
the primary tumour was suitable for cellular DNA
measurement, were selected. Clinical details of these
patients are included in Table I.
A standard proforma was completed for each
patient recording personal details, symptoms and
physical signs referrable to both the primary lesion
and distant metastases, the results of pre-operative
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Table I Details of 46 patients
presenting with synchronous
hepatic metastases from colorectal
cancer
Male=28 Female= 18
Mean age=62 years
Site R. Colon-12
L. Colon-17
Rectum -17
haematological and biochemical investigation,
operative findings and pathological examination of
the resected primary lesion. Accurate survival
figures were obtained from the hospital notes and
the Yorkshire Cancer Registry.
Nuclear DNA measurements on the paraffin
embedded primary tumour were performed using
a modification of the method of Hedley et al.
(1983), recently reported by Quirke et al. (1986).
Briefly, a 30,um section was cut from the paraffin
embedded block, dewaxed, rehydrated and disaggre-
gated using pepsin digestion. After centrifugation
at 2,000r.p.m. the pellet was washed and stained
in a solution of 4'-6-diamidino-2-phenylindole-
dihydrochloride (Boehringer Manheim, West
Germany) in RPMI 1640 tissue culture medium.
Following filtration samples were analysed on an
EPICS V flow cytometer (Coulter Electronics,
Hialeh, Florida, USA) using a coherent Innova
-905wUV enhanced argon ion laser. Ten
thousand nuclei were counted and DNA aneuploidy
was defined as the presence of more than one
GO/G1 peak. The DNA index was defined using
standard criteria (Hiddemann et al., 1984).
The clinical information together with the ploidy
value for the primary tumour was stored on
computer for statistical analysis. Survival plots for
different levels of individual clinical variables were
obtained using the BMDP-PIL programme based
on the method of Kaplan & Meier (1958) and tests
for statistical significance were computed using the
Mantel-Cox 'logrank' analysis.
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Figure 1 illustrates representative DNA histo-
grams from a diploid tumour (top) and a tumour
with a DNA aneuploid cell population. Of the 46
tumours, 27 (59%) were DNA aneuploid, the
remaining 19 being diploid. There appeared to be
no relationship between ploidy and the tumour
site, grade and presence or absence of lymph node
metastases. No significant difference between the
Kaplan-Meier survival plots for DNA aneuploid
and diploid tumours was found as illustrated in
Figure 2. The clinical factors within this group of
patients which did appear to have prognostic
significance included percentage liver involvement
by tumour, distribution of liver metastases, tumour
grading and clinical enlargement of the liver. The
median survival and levels of significance for these
individual prognostic factors are summarized in
Table II.
The prognosis for patients with synchronous
hepatic metastases from primary carcinomas of the
colon and rectum is poor; median survivals ranging
from 6-10 months (Finan et al., 1985; Pestana et al.,
1964; Jaffe et al., 1968). Many factors have been
identified which significantly alter the prognosis
(Goslin et al., 1982; Lahr et al., 1983; Finan et al.,
1985). Although several of these relate to the extent
of hepatic replacement by tumour or the distribu-
tion of metastases within the liver, other prognostic
factors can be obtained from examination of the
primary tumour, e.g., stage, grade and local fixity.
Three recent studies on colorectal cancer (Wolley
et al., 1982; Armitage et al., 1985; Quirke et al.,
personal communication) have shown that the
presence of DNA aneuploidy within the primary
tumour is of poor prognostic significance. Wolley et
al., studying 33 patients and following them for 3-5
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Figure 1 Examples of histograms of DNA content
obtained from colorectal carcinomas.
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Figure 2 Survival curves obtained for diploid and DNA aneuploid tumours.
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Table II Significant variables affecting survival in
patients presenting with synchronous hepatic metastases
Median
survival P value
(months) (Mantel-Cox)
Percentage liver involvement
<20% 16
20-80% 6 0.002
Clinically enlarged liver
Yes 4 0.003
No 13
Distribution ofliver metastases
Single 16 0 Multiple 9 0.05
Tumour grading
Well/Moderate 11 0.05 Poor 7
years, noted that 12 of 13 cases in the non-diploid
group had died (survival 4-34 months) as compared
with only 6 of 20 in the diploid group. Similarly,
Armitage et al. and Quirke et al. noted that 43%
and 57% of patients with diploid tumours survived
5 years as compared with 19% and 34% of patients
with DNA aneuploid tumours. However all of these
studies were on patients with both local and
advanced disease. In addition, it has been
demonstrated recently that ploidy may be of some
use in a variety of pre-malignant conditions of the
colon e.g. colonic adenomas (Quirke et al., 1986;
Van den Ingh et al., 1985) and cases of long-
standing ulcerative colitis (Hammarberg et al.,
1984). Doubt remains, however, as to the value of
ploidy in patients with advanced colorectal
malignant disease.
Our findings that 59% of tumours analysed were
DNA aneuploid is in keeping with other series
(Armitage et al., 1985; Quirke et al., personal
communication). Like Armitage et al., we found no
significant association between ploidy and either
stage or grade of the primary tumour. However,
others have noted quite a marked association
between ploidy and staging (Banner et al., 1985). In
their subset of 25 'Dukes' D' cases (Armitage et al.,
1985) it is of interest to note that diploidy
conferred no particular advantage in terms of 5
year survival. Using survival plots and log rank
analysis, we too have been unable to show any
significant difference in survival between DNA
aneuploid and diploid tumours.
This finding mirrors the experience of workers
studying ovarian carcinoma. Friedlander et al.
(1984b) using multivariate analysis initially showed
tumour ploidy to be an independent prognostic
factor in patients with advanced ovarian cancer,
diploid tumours surviving significantly longer than
aneuploid tumours. However, more recently, they
have noted no such difference when analysing
patients with stage IV disease alone (overt
metastases beyond the peritoneal cavity) (Hedley et
al., 1985). Stuart-Harris et al. (1985) have not been
able to demonstrate any survival advantage in
patients demonstrating diploidy in locally recurrent
or metastatic breast cancer although this finding
may have been due to insufficient patient numbers
or to the variety of treatments adopted.
As in previous series (Goslin et al., 1982; Lahr et
al., 1983), we have been able to identify several
factors which influence overall survival and if one
expands this series then the number of significant
factors increases (Finan et al., 1985). It may be that
with a much larger series of patients a small
difference might be noted between diploid and
DNA aneuploid tumours. However, based on these
studies it would appear unlikely that the routine
measurement of ploidy in the primary tumour will
have any useful role in assessing the prognosis of
patients presenting with synchronous hepatic
metastases from colorectal cancer. The relationship
between DNA aneuploidy and response to
treatment however requires further investigation in
the light of recent reports that DNA aneuploid
tumours are more susceptible to chemotherapy
(Look et al., 1984; 3rd International Workshop on
Chromosomes in Leukaemia, 1983; Morgan et al.,
personal communication) and radiotherapy
(Wijkstrom et al., 1984).
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